US2015203570A1PendingUtilityA1

Prevention and treatment of pain using antibodies to sphingosine-1-phosphate

58
Assignee: LPATH INCPriority: Oct 24, 2008Filed: Oct 27, 2014Published: Jul 23, 2015
Est. expiryOct 24, 2028(~2.3 yrs left)· nominal 20-yr term from priority
Inventors:Roger A. Sabbadini
C07K 16/18C07K 16/44C07K 2317/76A61K 2039/505C07K 2317/24C07K 2317/565A61P 25/02A61P 29/00C07K 2317/56
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to use of anti-S1P agents, for example, humanized monoclonal antibodies, for prevention and/or treatment of pain, including neuropathic pain, hyperalgesia, allodynia, and chemotherapy-induced pain.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating or preventing pain in a human subject, comprising administering to a human subject having or believed to be at risk of having pain an antibody or fragment thereof that binds and neutralizes S1P, thereby effecting treatment or prevention of pain. 
     
     
         2 . The method of  claim 1  wherein the pain is neuropathic pain, allodynia, or hyperalgesia. 
     
     
         3 . The method of  claim 1  wherein the neuropathic pain is chemotherapeutic drug-induced neuropathic pain. 
     
     
         4 . The method of  claim 1  wherein the antibody is a monoclonal antibody. 
     
     
         5 . The method of  claim 4  wherein the antibody is a humanized antibody.

Join the waitlist — get patent alerts

Track US2015203570A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.